Severe Hypocalcemia Associated with Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians

Clinical Genitourinary Cancer

Volumn 13, Issue 4, 2015, Pages e305-e309

  Autio, Karen A ^a   Farooki, Azeez ^a   Glezerman, Ilya G ^a   Chan, Amelia ^a   Schneider, Coursen W ^a   Barr, Hallie C ^a   Seyboth, Brian M ^a   Kampel, Lewis J ^a   Danila, Daniel C ^a   Rathkopf, Dana E ^a   Slovin, Susan F ^a   Scher, Howard I ^a   Morris, Michael J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Denosumab; Hypocalcemia; Metastatic prostate cancer; Osteoclast; RANKL; Skeletal related event

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; PARATHYROID HORMONE; PHOSPHORUS; PROSTATE SPECIFIC ANTIGEN; STEROID; VITAMIN D; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ARTICLE; CALCIUM METABOLISM; CALCIUM URINE LEVEL; CASTRATION RESISTANT PROSTATE CANCER; CHEMOTHERAPY; HOSPITALIZATION; HUMAN; HYPOCALCEMIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHYSICIAN; RETROSPECTIVE STUDY; RISK FACTOR; TOTAL PARENTERAL NUTRITION; VITAMIN SUPPLEMENTATION; BONE NEOPLASMS; CASE REPORT; CHEMICALLY INDUCED; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SECONDARY; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADMINISTRATION, INTRAVENOUS; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CALCIUM; DENOSUMAB; HOSPITALIZATION; HUMANS; HYPOCALCEMIA; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RISK FACTORS;

EID: 84936986575     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2014.11.008     Document Type: Article

References (20)

1. K. Fizazi, M. Carducci, and M. Smith Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study Lancet 377 2011 813 822
2. S.A. Polyzos, A.D. Anastasilakis, and I. Litsas Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease J Bone Miner Metab 28 2010 706 712
3. T.L. Breen, and E. Shane Prolonged hypocalcemia after treatment with zoledronic acid in a patient with prostate cancer and vitamin D deficiency J Clin Oncol 22 2004 1531 1532
4. J.L. Gulley, S. Wu, and P.M. Arlen Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases Clin Genitourin Cancer 5 2007 403 405
5. US Department of Health and Human Services; National Institutes of Health; National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03, June 14, 2010. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.5x11.pdf. Accessed: December 4, 2014.
6. P.W. Kantoff, S. Halabi, and M. Conaway Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study J Clin Oncol 18 1999 2506 2513
7. A.J. Armstrong, E.S. Garrett-Mayer, and Y.C. Yang A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis Clin Cancer Res 13 2007 6396 6403
8. S. Halabi, E.J. Small, and P.W. Kantoff Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer J Clin Oncol 21 2003 1232 1237
9. R.J. Cook, R. Coleman, and J. Brown Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer Clin Cancer Res 12 2006 3361 3367
10. M. Lein, K. Miller, and M. Wirth Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid Prostate 69 2009 624 632
11. P.W. Kantoff, C.S. Higano, and N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
12. E.R. Dennis, X. Jia, and I.S. Mezheritskiy Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer J Clin Oncol 30 2012 519 524
13. M. Tucci, A. Mosca, and G. Lamanna Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease Prostate Cancer Prostatic Dis 12 2009 94 99
14. J.A. Riancho, R. Arjona, and R. Valle The clinical spectrum of hypocalcaemia associated with bone metastases J Intern Med 226 1989 449 452
15. M.I. Fokkema, L.J. de Heide, and W.D. van Schelven Severe hypocalcaemia associated with extensive osteoblastic metastases in a patient with prostate cancer Neth J Med 63 2005 34 37
16. M.F. Holick, N.C. Binkley, and H.A. Bischoff-Ferrari Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline J Clin Endocrinol Metab 96 2011 1911 1930
17. Institute of Medicine; Committee to Review Dietary Reference Intakes for Vitamin D and Calcium Dietary Reference Intakes for Calcium and Vitamin D 2011 National Academies Press Washington, DC
18. R.G. Russell Bisphosphonates: the first 40 years Bone 49 2011 2 19
19. Amgen. Prolia (denosumab): highlights of prescribing information. Available at: http://pi.amgen.com/united
20. F. Milat, S. Goh, and L.U. Gani Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer Bone 55 2013 305 308